Antitumor Benefits of Antiviral Immunity: An Underappreciated Aspect of Oncolytic Virotherapies

Shashi Gujar; Jonathan Pol; Youra Kim; Patrick W. Lee; Guido Guido Kroemer

doi:10.1016/j.it.2017.11.006

Related publications

Article2021

Regulation of antitumor immunity by inflammation-induced epigenetic alterations

Michael Karin, Shabnam Shalapour

Preprint2023

Itaconate enhances oncolytic virotherapy by multitarget inhibition of antiviral and inflammatory pathways

Naziia Kurmasheva, Aida Said, Boaz Wong, Alena Kress, Zhenlong Liu, Chen Wang, Madalina E. Carter-Timofte, Emilia Holm, Demi van der Horst, Huy‐Dung Hoang, Krishna Sundar Twayana, Rasmus N. Ottosen, Esben B. Svenningsen, Fabio Begnini, Ander Kiib, Hauke J. Weiss, Daniele Di Carlo, Michela Muscolini, Maureen Higgins, Priscilla Kinderman, Mirte van der Heijden, Tong Tong, Attila Ozsvár, Wen‐Hsien Hou, Vivien R. Schack, Christian K. Holm, Nadine van Montfoort, Yunan Zheng, Melanie C. Ruzek, Joanna Kalucka, Laureano de la Vega, Walid A. M. Elgaher, Anders Rosendal Korshoej, Rongtuan Lin, John Hiscott, Thomas B. Poulsen, Luke O'neill, Jean‐Simon Diallo, Henner F. Farin, Tommy Alain, David Olagnier

Research Square (Research Square)

Article1993

Antitumor Benefits of Antiviral Immunity: An Underappreciated Aspect of Oncolytic Virotherapies

Discussion(0)

Related publications

Regulation of antitumor immunity by inflammation-induced epigenetic alterations

Itaconate enhances oncolytic virotherapy by multitarget inhibition of antiviral and inflammatory pathways

A New Aspect of Warfarin Resistance in Wild Rats: Benefits in the Absence of Poison

Antiviral and antitumor activities of 5-substituted 2'-deoxyuridines.

Synthesis, Antiviral and Antitumor Activity of New 4‐Nitroimidazoles.